Email This Article
Headlines & Perspectives
Neurocrine's Elagolix Misses Main Study Goal
By
Adam Feuerstein
03/26/09 - 09:57 AM EDT
Patients treated for endometriosis with elagolix reported improved daily pelvic pain scores compared with placebo, but the difference wasn't statistically significant.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,295.94 | 1,097.73 | 2,196.74 | 35.05 |
Oil *
73.66
|
|
DOWN
12.32
|
UP
1.66
|
UP
16.69
|
UP
0.18
|
10 Yr
3.50%
SPDR Gold
108.73
|
|
-0.12%
|
+0.15%
|
+0.77%
|
+0.52%
|
Data delayed 20 minutes |
Connect with TheStreet